These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24966622)

  • 21. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C.
    Sugano S; Suzuki T; Watanabe M; Ohe K; Ishii K; Okajima T
    Am J Gastroenterol; 1998 Dec; 93(12):2441-4. PubMed ID: 9860406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis.
    d'Alteroche L; Majzoub S; Lecuyer AI; Delplace MP; Bacq Y
    J Hepatol; 2006 Jan; 44(1):56-61. PubMed ID: 16223542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C: a review of diagnosis, management, and ocular complications from treatment.
    Tsolakos A; Zalatimo N
    Optometry; 2003 Aug; 74(8):517-23. PubMed ID: 12926825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does ascorbic acid prevent retinopathy during interferon therapy in patients with chronic hepatitis C?
    Nishiguchi S; Shiomi S; Enomoto M; Lee C; Jomura H; Tamori A; Habu D; Takeda T; Yanagihara N; Shiraki K
    J Gastroenterol; 2001 Jul; 36(7):486-91. PubMed ID: 11480793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
    Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis.
    Coppola N; Pisaturo M; Tonziello G; Sagnelli C; Sagnelli E; Angelillo IF
    BMC Infect Dis; 2012 Dec; 12():357. PubMed ID: 23245594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.
    Schulman JA; Liang C; Kooragayala LM; King J
    Ophthalmology; 2003 Feb; 110(2):437-42. PubMed ID: 12578794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Retinopathy in a patient with hepatitis C treated with pegylated interferon and ribavirin: case report].
    Avila MP; Freitas AM; Isaac DL; Bastos AL; Pena RV
    Arq Bras Oftalmol; 2006; 69(2):255-9. PubMed ID: 16699680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferon-related retinopathy in a man with chronic hepatitis C].
    Viennet A; Glatre F; Bacin F
    J Fr Ophtalmol; 2009 Sep; 32(7):505-10. PubMed ID: 19592135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.
    Sugawara K; Inao M; Nakayama N; Mochida S
    J Gastroenterol; 2014 Feb; 49(2):363-8. PubMed ID: 24081655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C.
    Nagaoka T; Sato E; Takahashi A; Yokohama S; Yoshida A
    Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):368-75. PubMed ID: 17197556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials.
    Zhang CH; Xu GL; Jia WD; Li JS; Ma JL; Ge YS
    Int J Cancer; 2011 Sep; 129(5):1254-64. PubMed ID: 21710498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
    Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
    Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin.
    Novelli FJ; Przysiezny A; Rosa EL; Garcia RF; Nóbrega MJ
    Arq Bras Oftalmol; 2014; 77(3):178-81. PubMed ID: 25295906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Bal T; Onlen Y
    Arab J Gastroenterol; 2018 Mar; 19(1):33-36. PubMed ID: 29503077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.